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A B S T R A C T
Objective: Uterine fibroids are the most common benign tumours in women of the reproductive age.
Symptoms of heavy menstrual bleeding, abdominal discomfort and infertility may seriously affect a woman’s
quality of life. Uterine artery embolization is a safe and effective alternative treatment to hysterectomy or
myomectomy for symptomatic uterine fibroids. Which treatment provides the highest quality of life, least
complications, symptom reduction and least chance intervention, has not been established and might depend
on strict patient selection. This study aims to identify which specific subgroups benefit most of each treatment
by analyzing individual participant data derived from randomized controlled trials of women undergoing
embolization or surgical treatment. This study will primarily assess the effectiveness of both treatment groups
byevaluatingtheeffectonqualityof lifeofembolizationincomparisontosurgeryonspecificpatientandfibroid
characteristics and the possible need for re-intervention for fibroid-related symptoms.
Data sources: PubMed/MEDLINE, Embase and The Cochrane Library were searched up to August 2020.
Study eligibility criteria: We will collect individual participant data from randomized controlled trials that
studied clinical and procedural outcomes of premenopausal women with symptomatic uterine fibroids,
who were randomized between uterine artery embolization and surgery.
Study appraisal and synthesis methods: Individual participant data from all eligible trials will be sought and
analysed according to intention-to-treat principle. Risk of Bias will be done by using version 2 of the
Cochrane tool for Risk of Bias in randomized trials. Subgroup analyses to explore the effect of e.g. age,
fibroid characteristics and fibroid complaints will be performed, if data is available. This individual patient
data meta-analysis will be analysed according to a one-stage model.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
Introduction
Uterine fibroids are the most common benign tumours inwomen
of the reproductive age, with a reported prevalence ranging from 5%
Abbreviations: IPD-MA, individual participant data meta-analysis; QoL, quality
of life; RCT(s), randomized controlled trials; RoB, risk of bias; UAE, uterine artery
embolization.
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Although these neoplasms rarely show malignant transformations,
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omplaints may prevent women from participating in normal daily
ctivities and significantly decrease their quality of life (QoL) [2,3].
he impact of fibroids on fertility depends on their location [4].
reatment options range from medicinal treatment, to minimally
nvasive procedures such as uterine artery embolization (UAE), and
ore invasive surgical treatment in the form of myomectomy or
ysterectomy [5]. Patient preference may be influenced by a wish to
reserve fertility, avoid radical surgery, or the need for a permanent
olution. Treatment options can depend on fibroid characteristics,
hich can complicate the counselling of patients [6]. Multiple
andomized controlled trials (RCTs) have proven UAE to be a safe and
ffective alternative to surgical treatment for symptomatic uterine
broids [7–11], up to tenyears after treatment [12], but balanced by a
ignificant risk of re-intervention, which is estimated to be 15–32%
13].
Uncertainty remains with regards to whether specific patient
haracteristics and the underlying nature of the fibroid impact
reatment outcomes. Volkers et al. attempted to identify risk
actors for technical failure or complications of UAE and found that
atients with single fibroid tumours and/or small uterine volumes
ave a higher risk of procedural failure, such as incomplete
nfarction [14]. Identification of predictive factors for effectiveness
nd safety has thus far been complicated by the small sample sizes
nd non-comparable patient baseline characteristics of the
ndividual studies, often including a non-randomized setting [15].
ationale for a systematic review with individual participant data
eta-analysis comparing UAE with surgical treatment
The current evidence has highlighted the trade-off between the
ess invasive nature of UAE and the need for re-intervention,
ompared with surgical procedures. Many clinical guidelines
ecommend that the choice of procedures should lie with the
nformed patient [6,16]. To enable that women requiring treatment
ake informed choices, it is essential to identify which patients
xperience greatest benefit for either treatment method.
ollaborative approach
This individual participant data meta-analysis (IPD-MA) will be
n international collaboration involving all trial investigators who
onducted eligible RCTs and the IPD-MA research team (MAM;
H; BWM; JM, OW) to evaluate all available data.
bjectives
This study aims to assess the efficacy of UAE compared with
urgical treatment in women with uterine fibroids. In particular,
his study aims to determine how the patient and disease
haracteristics may predict clinical and QoL outcomes, thereby
ffering clinicians selection criteria to make recommendations on
reatment success.
rimary outcomes
The primary questions of our individual patient data meta-
nalysis is which patients undergoing UAE compared to surgical
reatment, have:
b Any non-scheduled re-intervention to treat short and long-
term complications in either groups.
Secondary outcomes
1 Subgroup analyses of the primary outcomes will be done for the
separate surgical treatment groups (myomectomy and hyster-
ectomy).
2 Multivariate analysis to identify patient characteristics, that are
of:
o Highest improvement of QoL
o Least chance for re-intervention
o Symptom reduction
3 Subgroup analysis will be done for different patient character-
istics to identify possible predictors for secondary myomectomy
or hysterectomy in the UAE group.
4 Multivariate analysis will be done for different patient
characteristics to identify possible predictors for a chance on
a best possible outcome, defined as: no re-intervention and  10
points improvement on any QoL scale or symptom reduction
scale.
Primary outcomes will be measured at 12 months of follow up.
Different time points will be explored for the secondary outcomes.
If sufficient data are available, a network meta-analysis will
compare all treatment options (UAE, hysterectomy and myomec-
tomy) and patient characteristics.
Methods
Protocol development and registration
This protocol was registered in PROSPERO (CRD42018098676)
and is reported in accordance with the Preferred Reporting Items
for Systematic review and Meta-analysis Protocols (PRISMA-P)
2015 statement [17]. Investigators from all identified trials were
invited to contribute or comment on this protocol. All correspon-
dence regarding the development of this protocol has been
recorded. Ultimately, the IPD-MA team was responsible for making
methodological decisions. The IPD meta-analysis will be con-
ducted according to the Cochrane Collaboration methodology and
reported in line with the PRISMA IPD statement.
Eligibility criteria
We will include RCTs that report on clinical and procedural
outcomes (outcomes) of women with symptomatic uterine
fibroids (population) who underwent either uterine artery
embolization (intervention) or surgical treatment (comparison).
Surgical treatment include myomectomy and hysterectomy, both
laparoscopic and open approach or (combined) vaginal approach
in case of hysterectomy. Hysteroscopic surgery is excluded. There
will be no restrictions on dates or language. We aim to include all
relevant RCTs, irrespective of whether they were published, had
completed recruitment or had completed their analyses.
Information sources and search strategy The highest improvement of QoL, or if unavailable, the greatest
symptom reduction.
 The least chance of re-intervention.
a Re-intervention is defined as any intervention after initial
treatment to treat persisting or recurring symptoms in either
groups.18To identify all trials eligible for inclusion in this IPD, preliminary
literature searches and screening were conducted (Appendix 1:
Study characteristics and Appendix 2: Search strategy). These
searches were conducted as part of the development of this
protocol so that the protocol could be sent to the investigators of
the trials, along with an invitation to join this project.0
M.-A. Middelkoop, M.J. Harmsen, I. Manyonda et al. European Journal of Obstetrics & Gynecology and Reproductive Biology 256 (2021) 179–183More detailed searches will be conducted in PubMed/MEDLINE
(MeSH terms and tiab searches), The Cochrane Library (Cochrane
Database of Systematic Reviews), and EMBASE (Emtree and tiab
searches). To increase the likelihood of identifying all relevant
studies, the reference lists of eligible studies will be searched for
additional studies. The meta-register of controlled trials and the
ISRCTN will be searched to identify any ongoing RCTs. We will
contact the corresponding author of all published studies, and the
named registry contract for unpublished studies, to retrieve
individual participant data.
The search strategy include terms relating to or describing the
population, intervention, comparison, and study design. The
search terms are adapted for use in the distinct bibliographic
databases as well as the database-specific filters. The full search
strategy as applied in Pubmed/MEDLINE format can be found in
Appendix 2.
Study selection
Literature search is aimed at identifying trials. Titles and
abstracts of studies retrieved from the search strategy will be
screened independently by two reviewers. Articles will be included
or excluded according to the stated criteria. Any discrepancies
between the two reviewers in this process will be discussed, and
full text accessed for further clarification when needed. If
discrepancies continue to exist, a third independent reviewer will
be consulted and the article will be discussed among the
researchers until consensus is reached. All duplicate articles
included for full-text screening will be removed. A manual revision
of duplicates to be deleted will be performed for verification. Trials
that were excluded from the IPD-MA will be listed with their
reason for exclusion.
Data acquisition and management
The data centre is located in the Department of Obstetrics and
Gynaecology at the Amsterdam University Medical Centers, the
Netherlands, who will manage transferring and sharing of the data.
Corresponding authors of the included articles will be asked to
share their individual participant data. When the author is either
not willing to share the data or no contact could be established
after repeated attempts (post/email/telephone/personal contact),
two independent reviewers will extract published data from
manuscripts following standardized data extraction forms. All
collected data will be stored in a master database constructed for
this IPD. These data will be cleaned and cross-checked against
published results in the articles. When discrepancies exist, the
authors will be contacted for clarification.
The participating investigators will be able to supply their data
via a secure data transfer platform. We will also request trial
protocols, forms, data dictionaries, and statistical analysis plans for
the included trials. We will request a minimum list of data items
(Appendix 3). An investigator is welcome to supply the data,
whether limited to the minimum items or the complete dataset, in
any manner that suits their convenience. The data must be
anonymized before transfer. No attempts will be made by the IPD-
MA team to re-identify participants. Access to the database will be
limited to the IPD-MA team.
The quality assurance will be done when the data is received by
the IPD-MA team. The data will be checked for consistency against
reported baseline characteristics, trial flow chart and primary
analyses cannot be replicated from the IPD will be exclude from the
IPD-MA.
Assessment of risk of bias
All selected trials will be assessed for risk of bias (RoB) using the
received datasets and the reported information. Risk of bias will be
assessed in all articles using version 2 of the Cochrane Risk of Bias in
randomized trials (RoB 2) [18]. For each outcome, each study is
assessed for a specific result on 6 points: 1) Specify results being
assessed; 2) Specify effect of interest; 3) List sources of information
used to inform assessment; 4) Answer signaling questions; 5) Judge
RoB for each domain; 6) Judge overall RoB for the result. For the
complete syntheses these judgements are integrated into results and
conclusions. The different domains regard the bias arising from
randomization process, intended interventions, missing outcome
data, measurement of the outcome, selection of the reported result
and eventually the overall bias. Concluding in a RoB judgement: low
or high RoB or ‘some concerns’. The assessment will be conducted by
one member of the IPD-MA research team and independently
checked by a second member of the IPD-MA team.
Data synthesis
Before the data is synthesized, all data will be checked to ensure
only appropriate data is used and all available data for subgroup
and predictor analyses is incorporated. We will report the gathered
data according to the PRISMA guidelines for a systematic review
and meta-analysis of individual participant data.
Statistical analysis
Descriptive tables will be developed to outline the study and
population characteristics by intervention (UAE) and comparator
arms (surgery). Appendix 3 lists the data items that will be
requested. All data will be checked for missing data, assessed for
distribution and analysed in order to reproduce the initial
published results. Data will be analysed according to an intention
to treat principle, so that each participant will be analysed in
conformance with the allocated treatment. All statistical analyses
will be performed using STATA (SE 14.1).
Outcome measures
The difference between treatment arms will be reported as
mean with standard deviation (or median in case of a non-normal
distribution) for continuous outcomes (e.g. quality of life).
Dichotomous outcomes (e.g. re-intervention yes/no) will be
analysed by calculating the risk ratio for the effect of embolization
compared to surgical treatment of uterine fibroids. When a risk
ratio cannot be calculated, an odds ratio will be used. The
relationship between continuous variables and the main outcome
(QoL) will be explored through application of generalized linear
mixed models [19]; linear mixed models will be applied to
continuous outcomes, and logistic mixed-effect models to calcu-
late a relative risk or odds ratio for dichotomous outcomes.
One-stage and two-stage modelthe data dictionary or form, baseline differences and if correct
randomization was done. The raw baseline data, trial flow chart
(Consort diagram) and primary analyses will be repeated using the
IPD received and compared to the reported data in the study
publication. Any inconsistencies will be noted, and discussed with
the investigator of the study and the IPD-MA team. Trials where the181The IPD will be analysed according to the ‘one-stage’ model,
where we analyse the individual data of all studies combine with a
single model, but take clustering into account. We will use
multilevel logistics regression models with random effects models,
thereby clustering on individual study level to account for
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n all subgroups. In order to do this, we will develop generalized
inear mixed models to test how various patient characteristics
elate to the outcome, while accounting for potential heterogene-
ty across trials. The variables to be tested and outcomes to be
ddressed in these multilevel models will depend on the available
ata from the participating studies. If sufficient data are available, a
etwork meta-analysis will compare all treatment options (UAE,
ysterectomy and myomectomy) and patient characteristics.
When possible, a two-stage model will be performed to do a
ensitivity analysis with the aggregated data from the trials that
id not provide data.
nalysis of potential effect modifiers
To find which patients derive greater benefit (or harm) from
ntervention (UAE) compared to surgery, we will investigate
otential effect modifiers at intervention and patient level. The
atients included in this IPD will be divided into groups according
o intervention- or trial level, and a multivariate meta-regression
pproach will be performed. One-stage models will then be used to
nalyse the effect of the potential effect modifiers by adding them
o existing one-stage models, enabling assessment of multiple
nterventions and patient level characteristics.
Potential effect modifiers on intervention level
 Type of surgical intervention: myomectomy, or hysterectomy
 Type of surgical approach: abdominal, vaginal, laparoscopic
Potential effect modifiers on patient and fibroid level
 Uterine volume (cm3)
 Number of fibroids
 Fibroid volume (dominant fibroid, cm3)
 Location of dominant fibroid: submucosal, intramural and
subserosal
 Symptoms: menorrhagia, dysmenorrhea, pain, urinary symp-




ime to event analyses
The association between the time to first re-intervention and
ubsequent re-interventions and patient level risk factors can be
alculated within each trial by using an appropriate time-to-event-
nalysis.
issing data
If data from trials are missing because the investigators decided
ot to participate or did not respond to our invitation to join this
PD-MA collaboration, we will extract aggregate data from the
ublished article and combine these with the results from the IPD-
A in a sensitivity analysis.
If covariate data are missing for some participants, these
atients will in the first instance be excluded from the analysis. In
ase there is substantial missing data (>10% for an outcome or
outcome data across the trials will be compared by performing
sensitivity analyses with and without these studies.
Ethics approval and consent to participate
All individual studies to be included in this individual
participant data meta-analysis should have obtained ethical
approval from their respective ethics committees. Only anony-
mous data will be analysed. The results of this study will be
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Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.ejogrb.2020.11.027.
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